These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8336195)

  • 1. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
    Chahinian AP; Antman K; Goutsou M; Corson JM; Suzuki Y; Modeas C; Herndon JE; Aisner J; Ellison RR; Leone L
    J Clin Oncol; 1993 Aug; 11(8):1559-65. PubMed ID: 8336195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
    Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
    Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
    Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
    Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
    Kindler HL; Belani CP; Herndon JE; Vogelzang NJ; Suzuki Y; Green MR
    Cancer; 1999 Nov; 86(10):1985-91. PubMed ID: 10570422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
    Kindler HL; Herndon JE; Zhang C; Green MR;
    Lung Cancer; 2005 Jun; 48(3):423-8. PubMed ID: 15893012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
    van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
    J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].
    Tsavaris N; Primikirios N; Mylonakis N; Varouchakis G; Dosios T; Pavlidis N; Skarlos D; Tasopoulos T; Dritsas J; Kosmidis P
    Anticancer Res; 1997; 17(5B):3799-802. PubMed ID: 9427783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
    Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
    J Clin Oncol; 1994 Jun; 12(6):1156-63. PubMed ID: 8201377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
    O'Brien ME; Watkins D; Ryan C; Priest K; Corbishley C; Norton A; Ashley S; Rowell N; Sayer R
    Ann Oncol; 2006 Feb; 17(2):270-5. PubMed ID: 16317014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
    Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
    Tsavaris N; Mylonakis N; Karvounis N; Bacoyiannis C; Briasoulis E; Skarlos D; Pavlidis N; Stamatelos G; Kosmidis P
    Lung Cancer; 1994 Sep; 11(3-4):299-303. PubMed ID: 7812707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.
    Hesdorffer ME; Chabot JA; Keohan ML; Fountain K; Talbot S; Gabay M; Valentin C; Lee SM; Taub RN
    Am J Clin Oncol; 2008 Feb; 31(1):49-54. PubMed ID: 18376228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
    Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
    J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
    Pinto C; Marino A; De Pangher Manzini V; Benedetti G; Galetta D; Mazzanti P; Del Conte G; dell'Amore D; Piana E; Giaquinta S; Lopez M; Martoni A
    Lung Cancer; 2006 May; 52(2):199-206. PubMed ID: 16542747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of remission induced in diffuse pleural malignant mesothelioma by the treatment with cisplatin and doxorubicin].
    Niki Y; Nakayama S; Soga T; Baba M; Nishimura A; Kato M; Kanamaru M
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3635-8. PubMed ID: 2817912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.